Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC
Ontology highlight
ABSTRACT: This study is try to evaluate the effect of cetuximab monotherapy as maintenance treatment, versus continuation after 8 courses of induction therapy with cetuximab plus standard chemotherapy regimen (FOLFIRI or mFOLFOX6)in metastatic colorectal cancer (mCRC) patients. The maintenance treatments are continued until disease progression or untolerated toxicity. The aim of this study is to demonstrate that cetuximab monotherapy is non-inferior to continuation treatment, in those mCRC patients who responded to induction therapy(SD, PR, or CR), and carry biomarker-panels (KRAS, NRAS, BRAF, and PIK3CA) favor EGFR antibody.
DISEASE(S): Colorectal Cancer,Colorectal Neoplasms
PROVIDER: 2228220 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA